SLS — SELLAS Life Sciences Group, Inc. - Common Stock
Session close: $19.15. Regular-session share volume: 88,227,603. Change from previous close: +156.36%.
Key developments
Management said it plans to engage with the FDA on an accelerated approval pathway and is preparing a Biologics License Application. That regulatory path is the key forward development to watch, since the reported benefit still depends on agency review.
Company mentioned — Mentions SLS in the article text. SELLAS Life Sciences Announces Positive Topline Results from Pivotal Phase 3 REGAL Trial
News sources
Company mentioned — Mentions SLS in the article text. SELLAS Life Sciences stock soars 240% on positive cancer trial · Company mentioned — Mentions SLS in the article text. SELLAS Life Sciences Announces Positive Topline Results from Pivotal Phase 3 REGAL Trial